VIP (5mg)
Specyfikacja techniczna
| Czystość (HPLC) | ≥95% (HPLC) |
| Numer CAS | 37221-79-7 |
| Forma | White lyophilized powder |
| Przechowywanie | -20°C |
| Sekwencja | His-Ser-Asp-Ala-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn-NH₂ |
| Masa cząsteczkowa | 3,326.82 g/mol |
| Forma soli | Acetate |
| Rozpuszczalność | Soluble in water |
VIP (5mg)
Cena katalogowa w EUR · HU, SK, CZ, PL
- Eurozone (EUR)80,00 EUR
- Węgry (HU)80,00 EUR≈ 32 000 Ft
- Słowacja (SK)80,00 EUR
- Czechy (CZ)80,00 EUR≈ 2 000 Kč
- Polska (PL)80,00 EUR≈ 340,00 zł
Ta sama cena katalogowa w EUR przy dostawie na Węgry, Słowację, Czechy i Polskę. Płatność w EUR.
Orientacyjne kwoty HUF, CZK i PLN przeliczone z EUR; Słowacja stosuje EUR. Kursy przybliżone. Płatność w EUR.
VIP (Vasoactive Intestinal Peptide) — 28-aminokwasowy neuropeptyd z receptorami VPAC1/VPAC2; w modelach immunomodulacji, zapalenia i rytmu dobowego. Wyłącznie RUO — do badań laboratoryjnych; nie do spożycia przez ludzi.
Wyłącznie do badań laboratoryjnych.
Nie do spożycia przez ludzi, zastosowań weterynaryjnych ani diagnostycznych.
From the Peptide Explorer
A 28-amino-acid neuropeptide found throughout the central and peripheral nervous systems, GI tract, and immune cells. VIP acts on VPAC1 and VPAC2 receptors to mediate vasodilation, smooth muscle relaxation, immune regulation, and neuroprotection across multiple organ systems.
Key Mechanisms
- ›VPAC1/VPAC2 receptor agonism
- ›Vasodilation via cAMP
- ›Anti-inflammatory cytokine regulation
- ›Neuroprotective signaling
- ›Smooth muscle relaxation
Primary Research Areas
- ›Neuroprotection
- ›Autoimmune disease
- ›Lung protection
- ›GI motility
- ›Vasodilation
Key Research Findings
- Demonstrated neuroprotective effects in Parkinson's and Alzheimer's models
- Aviptadil (synthetic VIP) advanced to clinical trials for ARDS
- Potent anti-inflammatory effects in autoimmune disease models
Research Overview
A 28-amino-acid neuropeptide found throughout the central and peripheral nervous systems, GI tract, and immune cells. VIP acts on VPAC1 and VPAC2 receptors to mediate vasodilation, smooth muscle relaxation, immune regulation, and neuroprotection across multiple organ systems.
Origin: Discovered in porcine intestinal extracts by Said & Mutt, 1970
Mechanism of Action
- VPAC1/VPAC2 receptor agonism
- Vasodilation via cAMP
- Anti-inflammatory cytokine regulation
- Neuroprotective signaling
- Smooth muscle relaxation
Primary Research Areas
- Neuroprotection
- Autoimmune disease
- Lung protection
- GI motility
- Vasodilation
Key Published Findings
- Demonstrated neuroprotective effects in Parkinson's and Alzheimer's models
- Aviptadil (synthetic VIP) advanced to clinical trials for ARDS
- Potent anti-inflammatory effects in autoimmune disease models
Research Protocol
Commonly studied routes: Intravenous, Subcutaneous, Intranasal. Reconstitute with bacteriostatic water. Consult published literature for dose ranges; use our Peptide Calculator for volumetric preparation.
Storage
-20°C lyophilized
Important Notice
VIP (5mg) is supplied for laboratory research use only (RUO). Not for human or veterinary use, diagnostics, or therapeutics.
Specyfikacja badawcza
Synthesized for strict analytical consistency. Verified via HPLC/MS.Zobacz standardy jakości →
Przechowywanie i obsługa
- Store lyophilized at -20°C
- Protect from light and moisture
- Use sterile bacteriostatic water for reconstitution
- Minimize freeze-thaw cycles
- Solubility: Soluble in water